CLINICAL_TRIALS trial_result · 2013-07-08

Clinical Trial Update: Safety And Efficacy Of UK-432,097 In Chronic Obstructive Pulmonary Disease. [Phase 2]

Pfizer conducted a Phase 2 trial of UK-432,097 for chronic obstructive pulmonary disease. The study was terminated and results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: TERMINATED | Results posted: 2013-07-08